Evidence map›Paper›PMID 39182110›Full record

ArticleHarm reduction journal2024

The fentanyl made me feel like I needed more methadone": changes in the role and use of medication for opioid use disorder (MOUD) due to fentanyl.

Maria Bolshakova, Kelsey A Simpson, Siddhi S Ganesh, Jesse L Goldshear, Cheyenne J Page, Ricky N Bluthenthal

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Harm reduction journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07148206 (Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07148206 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

TypeinterventionalSponsorMontefiore Medical CenterRan2026 to 2028Enrolled40ConditionsOpioid Use DisorderArmsDronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maria BolshakovaKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Kelsey A SimpsonKeck School of Medicine, University of Southern California, Los Angeles, CA, USA. k4simpson@health.ucsd.edu.
Siddhi S GaneshKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jesse L GoldshearKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Cheyenne J PageKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Ricky N BluthenthalKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Funding

Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
Cannabis use and health outcomes among opioid-using people who inject drugs in the context of cannabis legalizationR01DA046049 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BLUTHENTHAL, RICKY N, CORSI, KAREN F · 2019 to 2022
$2.6M
Institute for Addiction Science pilot award PG1033682NIDA NIH HHS R01 DA046049NIDA NIH HHS R01-DA046049NIDA NIH HHS T32 DA023356NIH grant T32DA023356NIH grant T32DA023356-13
6 · The paper itself

Abstract

backgroundFentanyl and fentanyl analogues have disrupted the illicit drug supply through contamination of other substances (i.e., methamphetamine and cocaine) and replacement of heroin in illicit markets. Increasingly, they are contributing to opioid-overdose related deaths. The rapid and growing presence of fentanyl has led to gaps in research on the impact of this illicit market change on people who use drugs (PWUD). We sought to examine how the changing opioid market and growing fentanyl availability influences the role and use of medication for opioid use disorder (MOUD).

methodsSemi-structured qualitative interviews were conducted with a community recruited sample of PWUD (N = 22) in Los Angeles, California between September 2021 and April 2022. Interviews examined opioid use history, current opioid use behaviors and consumption patterns, and MOUD experiences and perceptions. Thematic analysis was used to systematically code and analyze textual interview data.

resultsThe following themes related to fentanyl use and MOUD emerged: (1) Use of deviated MOUD to address fentanyl contamination, (2) Changing perception of the effectiveness of MOUD on fentanyl, and (3) Regulatory limitations of MOUD for fentanyl use disorder.

conclusionsPWUD described several repertoires for adjusting to changes in the illicit market of opioids. Clinicians treating PWUD should ask about recent fentanyl use prior to starting MOUD to account for increased tolerance to opioids. Harm reduction strategies such as naloxone kits, safe supply, and supervised consumption facilities can all prevent overdose deaths due to fentanyl.

Indexed as

FentanylMethadoneOpiate Substitution TreatmentOpioid-Related DisordersAdultAnalgesics, OpioidFemaleHumansLos AngelesMaleMiddle AgedQualitative ResearchAnalgesics, OpioidFentanylMethadone

Identifiers

PMID39182110
PMCPMC11344386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.